European Companies Search Engine
EU funding (€8,649,616): Improving treatment efficacy in hypertension by biomarker-guided personalised decision support Hor28 Nov 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Improving treatment efficacy in hypertension by biomarker-guided personalised decision support
In HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification biomarkers as companion diagnostics for the prescription of existing drugs. HT is the most important global risk factor for death and morbidity but is uncontrolled in more than 50% of patients. Causes of treatment failure include lack of identification of secondary forms such as endocrine hypertension (EHT) which can be curable by specific therapy. In addition, there is variable response to individual drugs and trial-and-error treatment leads to poor HT control and frustration for both patients and clinicians. The objective of HT-ADVANCE is to validate two multicomponent stratification biomarkers in patients with HT in order to i) identify patients with EHT, and ii) predict response to treatment in patients with primary hypertension. The hypothesis is that MOMICS biomarkers reflect specific forms of hypertension and susceptibility to specific drugs. To this end, we will run three clinical trials (HT-ENDO, HT-TREAT and HT-PREDICT) and apply machine learning techniques to integrate the genetic, genomic and metabolomic features that constitute the MOMICS biomarkers in order to generate accurate diagnostic and therapeutic response predictions for clinicians. We will also perform economic evaluation of the use of MOMICS for the treatment of HT, produce ethical and legal recommendations for clinical decision making, and develop a plan for their implementation as companion diagnostics. The study will be conducted by several HT Centres of Excellence and will build on the success of the ENSAT-HT project that has established methods and pipelines for integrating datasets derived from multiple platforms. We expect that HT-ADVANCE will provide a step change in the management of HT by enabling a personalised, more efficient and cost-effective treatment strategy, and importantly, will prevent the ensuing cardio-metabolic complications.
Funded Companies:
| Company name | Funding amount |
| The University of Birmingham | ? |
| Assistance Publique Hopitaux de Paris | €1,895,238 |
| Cliniques Universitaires Saint-LUC ASBL | €353,750 |
| HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GmbH | €547,315 |
| Inserm Transfert SA | €924,250 |
| Institut National de la Sante et de la Recherche Medicale | €1,615,852 |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | €2,151,058 |
| TECHNISCHE UNIVERSITAET DRESDEN | €527,375 |
| Universita Degli Studi Di Padova | €245,720 |
| Universita Degli Studi Di Torino | €183,784 |
| Universite de Toulouse | €205,275 |
Source: https://cordis.europa.eu/project/id/101095407
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: The University of Birmingham, Birmingham.
The visualizations for "The University of Birmingham - EU funding (€8,649,616): Improving treatment efficacy in hypertension by biomarker-guided personalised decision support"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
